AbCellera
Founded Year
2012Stage
IPO | IPOTotal Raised
$247.07MDate of IPO
12/11/2020Market Cap
1.72BStock Price
5.99About AbCellera
AbCellera (NASDAQ: ABCL) provides technologies to biotechnology and pharmaceutical partners. Its single-cell platform assists in the integration of capabilities for therapeutic antibody discovery through a combination of technologies including immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation. The company was founded in 2012 and is based in Vancouver, Canada.
AbCellera's Product Videos
Compete with AbCellera?
Ensure that your company and products are accurately represented on our platform.
AbCellera's Products & Differentiators
AbCellera Lead Panel
10 antibody sequences for development. Down-selected from diverse panels of antibodies based on: · Small-scale expression · Binding validation · Functional validation · High-throughput developability
Research containing AbCellera
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned AbCellera in 5 CB Insights research briefs, most recently on Dec 12, 2022.
Sep 28, 2020
Canadian Digital Health Market MapExpert Collections containing AbCellera
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AbCellera is included in 5 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,624 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Digital Health 150
150 items
The winners of the second annual CB Insights Digital Health 150.
Omics
1,267 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Digital Health
11,233 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma companies and and assistive tech developers.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AbCellera Patents
AbCellera has filed 4 patents.
The 3 most popular patent topics include:
- Animal viral diseases
- Animal virology
- Betacoronaviruses
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
6/22/2021 | 9/20/2022 | Immunology, Animal virology, Epidemiology, Animal viral diseases, Clusters of differentiation | Grant |
Application Date | 6/22/2021 |
---|---|
Grant Date | 9/20/2022 |
Title | |
Related Topics | Immunology, Animal virology, Epidemiology, Animal viral diseases, Clusters of differentiation |
Status | Grant |
Latest AbCellera News
May 4, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2023 Business Results
AbCellera Frequently Asked Questions (FAQ)
When was AbCellera founded?
AbCellera was founded in 2012.
Where is AbCellera's headquarters?
AbCellera's headquarters is located at 2215 Yukon Street, Vancouver.
What is AbCellera's latest funding round?
AbCellera's latest funding round is IPO.
How much did AbCellera raise?
AbCellera raised a total of $247.07M.
Who are the investors of AbCellera?
Investors of AbCellera include DCVC, Founders Fund, University of Minnesota, Presight Capital, OrbiMed Advisors and 12 more.
Who are AbCellera's competitors?
Competitors of AbCellera include Abveris and 6 more.
What products does AbCellera offer?
AbCellera's products include AbCellera Lead Panel and 1 more.
Who are AbCellera's customers?
Customers of AbCellera include Eli Lilly, Novartis, IGM Biosciences, Denali Therapeutics and Empirico.
Compare AbCellera to Competitors
Arctoris develops an automated drug discovery company. It combines its unique automation platform, Ulysses®, with advanced machine learning approaches and a team of seasoned drug hunters to guide and progress drug discovery programs in oncology and neurology. It offers on-demand access to various drug discovery assays conducted by robotics to biotech companies, pharmaceutical corporations, and academic centers. It was founded in 2016 and is based in Oxfordshire, United Kingdom.
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Integral Molecular develops technologies to enable the discovery and development of drugs that target integral membrane proteins, which are involved directly or indirectly in most major diseases, and comprise nearly half of all existing drug targets, including G protein-coupled receptors (GPCRs) and ion channels.
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Tizona Therapeutics is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system's function. In cancer, tumor cells evade recognition by controlling cells that suppress the proper function of the immune system. In autoimmune disease, the immune system attacks "self" tissues in the body due to insufficient regulation. Tizona's therapies are designed to regulate these suppressive cells, thereby either activating the body's ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. The company was founded in 2015 and is based in South San Francisco, California.
Isogenica specializes in the discovery and optimization of therapeutic and diagnostic peptides, proteins and antibodies. The company has an exclusive license to in vitro display technology that allows the generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.